Abstract
In this case study, we describe the use of in vitro protein evolution with ribosome display to improve the potency of a human interleukin-13-neutralising antibody by a factor of over 200-fold and derive a therapeutic candidate, CAT-354, for the treatment of asthma. A combination of directed and random mutagenesis enabled the identification of highly potent neutralising antibodies and highlighted the advantage of the ribosome display protein evolution approach in identifying beneficial mutations across the entire sequence space. This chapter describes in detail the process followed to achieve a successful in vitro affinity maturation outcome using ribosome display technology.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Reichert, J. M. Antibodies to watch in 2010, mAbs 2, 84–100.
Thompson, J., Pope, T., Tung, J. S., Chan, C., Hollis, G., Mark, G., and Johnson, K. S. (1996) Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity, Journal of molecular biology 256, 77–88.
Baker, K. P., Edwards, B. M., Main, S. H., Choi, G. H., Wager, R. E., Halpern, W. G., Lappin, P. B., Riccobene, T., Abramian, D., Sekut, L., Sturm, B., Poortman, C., Minter, R. R., Dobson, C. L., Williams, E., Carmen, S., Smith, R., Roschke, V., Hilbert, D. M., Vaughan, T. J., and Albert, V. R. (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator, Arthritis and rheumatism 48, 3253–3265.
Thom, G., Cockroft, A. C., Buchanan, A. G., Candotti, C. J., Cohen, E. S., Lowne, D., Monk, P., Shorrock-Hart, C. P., Jermutus, L., and Minter, R. R. (2006) Probing a protein-protein interaction by in vitro evolution, Proceedings of the National Academy of Sciences of the United States of America 103, 7619–7624.
Hanes, J., and Pluckthun, A. (1997) In vitro selection and evolution of functional proteins by using ribosome display, Proceedings of the National Academy of Sciences of the United States of America 94, 4937–4942.
Caramori, G., Ito, K., and Adcock, I. M. (2004) Targeting Th2 cells in asthmatic airways, Current drug targets 3, 243–255.
Lewis, L., and Lloyd, C. (2010) Optimisation of antibody affinity by ribosome display using site-directed or error-prone mutagenesis, in Ribosome Display and Related Display Technologies: Methods and Protocols (Jackson, R. H., and Douthwaite, J., Eds.), Humana Press, New York.
Kabat, E. A. Sequences of proteins of immunological interest 5th ed, Bethesda, MD : U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1991. NIH publication ; no. 91–3242.
Hawkins, R. E., Russell, S. J., and Winter, G. (1992) Selection of phage antibodies by binding affinity. Mimicking affinity maturation, Journal of molecular biology 226, 889–896.
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., and Johnson, K. S. (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library, Nature biotechnology 14, 309–314.
Persic, L., Roberts, A., Wilton, J., Cattaneo, A., Bradbury, A., and Hoogenboom, H. R. (1997) An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries, Gene 187, 9–18.
Karlsson, R., Michaelsson, A., and Mattsson, L. (1991) Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system, Journal of immunological methods 145, 229–240.
Miyazaki, K., and Arnold, F. H. (1999) Exploring nonnatural evolutionary pathways by saturation mutagenesis: rapid improvement of protein function, Journal of molecular evolution 49, 716–720.
Blanchard, C., Mishra, A., Saito-Akei, H., Monk, P., Anderson, I., and Rothenberg, M. E. (2005) Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354), Clin Exp Allergy 35, 1096–1103.
Oh, C. K., Faggioni, R., Jin, F., Roskos, L. K., Wang, B., Birrell, C., Wilson, R., and Molfino, N. A. An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males, British journal of clinical pharmacology 69, 645–655.
Singh, D., Kane, B., Molfino, N. A., Faggioni, R., Roskos, L., and Woodcock, A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma, BMC pulmonary medicine 10, 3.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Thom, G., Minter, R. (2012). Optimization of CAT-354, a Therapeutic Antibody Directed Against Interleukin-13, Using Ribosome Display. In: Douthwaite, J., Jackson, R. (eds) Ribosome Display and Related Technologies. Methods in Molecular Biology, vol 805. Springer, New York, NY. https://doi.org/10.1007/978-1-61779-379-0_22
Download citation
DOI: https://doi.org/10.1007/978-1-61779-379-0_22
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-61779-378-3
Online ISBN: 978-1-61779-379-0
eBook Packages: Springer Protocols